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Abstract
Introduction: H1N1 influenza can cause severe acute lung injury (ALI). Extracorporeal membrane oxygenation
(ECMO) can support gas exchange in patients failing conventional mechanical ventilation, but its role is still
controversial. We conducted a systematic review and meta-analysis on ECMO for H1N1-associated ALI.
Methods: CENTRAL, Google Scholar, MEDLINE/PubMed and Scopus (updated 2 January 2012) were systematically
searched. Studies reporting on 10 or more patients with H1N1 infection treated with ECMO were included.
Baseline, procedural, outcome and validity data were systematically appraised and pooled, when appropriate, with
random-effect methods.
Results: From 1,196 initial citations, 8 studies were selected, including 1,357 patients with confirmed/suspected
H1N1 infection requiring intensive care unit admission, 266 (20%) of whom were treated with ECMO. Patients had
a median Sequential Organ Failure Assessment (SOFA) score of 9, and had received mechanical ventilation before
ECMO implementation for a median of two days. ECMO was implanted before inter-hospital patient transfer in 72%
of cases and in most patients (94%) the veno-venous configuration was used. ECMO was maintained for a median
of 10 days. Outcomes were highly variable among the included studies, with in-hospital or short-term mortality
ranging between 8% and 65%, mainly depending on baseline patient features. Random-effect pooled estimates
suggested an overall in-hospital mortality of 28% (95% confidence interval 18% to 37%; I2 = 64%).
Conclusions: ECMO is feasible and effective in patients with ALI due to H1N1 infection. Despite this, prolonged
support (more than one week) is required in most cases, and subjects with severe comorbidities or multiorgan
failure remain at high risk of in-hospital death.
Introduction
H1N1 influenza has been the focus of substantial
research given its higher case fatality among younger
subjects and the potential for fulminant acute lung
injury (ALI) and acute respiratory distress syndrome
(ARDS) [1]. In light of observational and randomized
trials in support of extracorporeal membrane oxygena-
tion (ECMO), this approach has been advocated for and
employed in several cases of complicated H1N1 infec-
tion [2]. The premises for use of ECMO in these
patients, including ECMO-supported inter-hospital
transfer, have been mainly the young age, the relatively
low prevalence of comorbidities, and the likelihood for
reversible lung failure typical of these patients [3]. Yet,
there is uncertainty as to the risk-benefit balance of
ECMO in patients with H1N1 infection, given variability
in selection, procedural and logistic features involved in
the implementation of such a technically demanding
treatment [4].* Correspondence: landoni.giovanni@hsr.it1Department of Anesthesia and Intensive Care, San Raffaele Scientific
Institute, via Olgettina 60, Milan, 20132, Italy
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Whereas H1N1 influenza virus is currently in the post-
pandemic period, regional outbreaks are still ongoing
and thus defining more accurately the role of ECMO in
this condition is clinically relevant [4]. Moreover, lessons
learned from the experience with Influenza A H1N1
infection may prove informative and beneficial for the
management of similar instances of ALI.
Systematic reviews based on explicit and sound meth-
ods can increase statistical power, appraise quality of
clinical evidence, and inform current clinical practice
and future research efforts [5]. We thus performed a
systematic review focusing on the use of ECMO in
patients with H1N1 influenza.
Materials and methods
Design
This systematic review complies with Meta-analysis Of
Observational Studies in Epidemiology (MOOSE) and
Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) guidelines, and has been
registered online before submission [6-8]. Study search,
selection, abstraction and quality assessment were all
performed by two independent reviewers (GBZ, GL)
with divergences resolved after consensus.
Search
MEDLINE/PubMed was searched for articles on ECMO
in patients with H1N1 infection with the following
highly sensitive strategy: (influenza OR h1n1 OR pan-
demic OR epidemic) AND (ards OR (acute AND
respiratory AND distress AND syndrome) OR ali OR
(acute AND lung AND injury) OR arf (acute AND
respiratory AND failure) OR (pulmonary AND failure)
OR (pulmonary AND insufficiency) OR (respiratory
AND failure) OR (respiratory AND insufficiency)) AND
(ecmo OR (extracorporeal AND membrane AND oxyge-
nation)). In addition, CENTRAL, Google Scholar and
Scopus were also systematically queried. All searches
were updated on 2 January 2012. No language restric-
tion was enforced, and references from selected studies
as well as previous systematic reviews on the topic were
manually searched for additional studies (backward
snowballing).
Selection criteria
Citations were first screened at the title/abstract level
and, if potentially pertinent, (that is, containing any
direct or indirect reference to H1N1 infection and
ECMO), retrieved in full text and appraised according
to the following specifications. Inclusion criteria were
(all criteria should be concomitantly met for study inclu-
sion): a) study reporting on 10 or more patients; b) with
suspected or confirmed H1N1 influenza infection; c)
receiving ECMO. Exclusion criteria were (one criterion
was sufficient for study exclusion): a) inclusion of <10
patients with H1N1 infection treated ECMO (thereby,
any study reporting on fewer than 10 patients treated
with ECMO was excluded); b) duplicate publication (in
which case only the most recent report from the same
study group was included in the systematic review).
Use of a sample size cut-off was chosen pre hoc to
limit the undue influence of anecdotal cases and the
ensuing risk of imprecision and publication bias, in
keeping with prior systematic reviews on H1N1 infec-
tion [1,2].
Data abstraction and quality appraisal
Several study, patient, procedural and outcome features
were abstracted (Tables 1, 2, and 3), with the primary
outcome of the study being mortality at the longest fol-
low-up available. The validity of included studies was
appraised with the Newcastle-Ottawa scale [9].
Data analysis
Continuous variables are reported as median (first to
third quartile) and categorical variables as n (%). Meta-
analytic pooling was performed for outcome variables
with a random-effect generic-inverse-variance-weighting
approach, reporting results as summary point estimate
(95% confidence interval). Statistical consistency was
tested by means of I2 [5]. Exploratory meta-regression
analysis was performed to identify significant modera-
tors by means of inverse-variance weighted-least-squares
linear regression analysis. Small study effects (for exam-
ple, publication bias) were appraised by visual inspection
of funnel plots and Peters test. Statistical significance
was set at the 5% level, with two-tailed P-values
reported throughout. Computations were performed
with RevMan 5 (Danish Cochrane Center, Copenhagen,
Denmark) and SPSS 18 (IBM, Armonk, NY, USA).
Results
Literature searches identified 1,196 potentially relevant
citations (none in CENTRAL, 676 in Google Scholar,
167 in MEDLINE/PubMed and 332 in Scopus, plus an
additional 21 records), which, after thorough appraisal,
yielded a total of 8 eligible studies (Figure 1) [10-17].
Notably, as the Australia and New Zealand Intensive
Care (ANZIC) group published several reports, baseline,
procedural and outcome features were extracted from
multiple sources, but this cohort of patients was
included only once in the meta-analysis to avoid dupli-
cation issues [14,18].
All studies were observational in design, with multi-
center and prospective data collection in three (38%),
were conducted in the US, Europe or Oceania, and were
published in 2010 or 2011 in critical care or generalist
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journals (Table 1). Overall study validity was adequate,
with a median score of 7 on the Newcastle-Ottawa scale
appraising the quality of observational studies, notwith-
standing the non-randomized design of all of them.
A total of 1,357 patients were included who had
required intensive care unit admission for respiratory
failure due to confirmed or suspected H1N1 infection
(Table 2). Of these, 266 (19.6%) received ECMO. Median
age of those receiving ECMO was 36 years, with 43%
men, 39% prevalence of obesity (body mass index >30
kg/m2), 11% of diabetes and 11% of asthma or chronic
obstructive pulmonary disease. Notably, 20% of patients
were females in the peri-partum period.
Patients had a median SOFA score of 9, and had
received mechanical ventilation before ECMO implemen-
tation for a median of two days (Table 3). ECMO was
exploited for inter-hospital patient transfer in 72% of cases,
and in most cases (94%) veno-venous ECMO was used, as
veno-arterial ECMO was reserved for those presenting
with respiratory and systolic cardiac failure, or who were
unresponsive to veno-venous ECMO (as bail-out indica-
tion). ECMO was operated for a median of 10 days.
Table 1 Included studies
Study Journal Location Design Prospective Setting Newcastle-
Ottawa scale
Primary end-
point
Follow-up
Beutel et al. (2011) Crit Care Germany Registry Yes Single
center
7 Death In-hospital
Chenaitia et al. (2011) Eur J Emerg Med France Registry Yes Single
center
6 Death one
month
Dubar et al. (2011) PLoS One France Registry Yes Multicenter 7 Death In-hospital
Forrest et al. (2011) Intensive Care Med Australia Registry No Multicenter 8 Death In-hospital
Higgins et al. (2011) Anaesth Intensive Care Oceania Registry Yes Multicenter 7 Death In-hospital
Holzgraefe et al. (2010) Minerva Anesthesiol Sweden Registry No Single
center
6 Death three
months
Noah et al. (2011) JAMA USA Registry No Multicenter 7 Death In-hospital
Patroniti et al. (2011) Intensive Care Med Italy Registry yes Multicenter 8 Death In-hospital
Table 2 Key patient features
Study Patients
admitted to ICU
Patients
receiving ECMO
Case
definition
Age
(years)
Male
gender
Obese DM Asthmaor
COPD
Peri-
partum
SOFA
Beutel et al. (2011) 25 17 C 45 64% NA NA NA NA 11
Chenaitia et al. (2011) 32 11 CS 33 36% NA NA NA NA NA
Dubar et al. (2011) 315 11 C NA 0 NA NA NA 100% NA
Forrest et al. (2011) 17 17 CS 34 50% NA NA NA 5% 8
Higgins et al. (2011) 722 68 CS 36 48% 50% 15% 30% 16% NA
Holzgraefe et al. (2010) 13 13 C 31 38% 38% 23% 8% 23% NA
Noah et al. (2011) 80 69 C 37 38% NA 5% 10% 27% 9
Patroniti et al. (2011) 153 60 CS 39 57% 39% 6% 12% 8% 7
C, confirmed H1N1 infection; COPD, chronic obstructive pulmonary disease; CS, confirmed or suspected H1N1 infection; DM, diabetes mellitus; ECMO,
extracorporeal membrane oxygenation; NA, not available; SOFA, sepsis-related organ failure assessment
Table 3 Key procedural and outcome data
Study Pre-ECMO
ventilation (days)
Transporton
ECMO
Veno-venous
ECMO
ECMO duration
(days)
Mortality in
ECMO patients
ICU stay
(days)
Total length of
stay (days)
Beutel et al. (2011) NA NA 100% 10 48% NA NA
Chenaitia et al. (2011) NA 100% 100% NA 65% NA NA
Dubar et al. (2011) NA NA NA 8 18% NA NA
Forrest et al. (2011) NA NA 94% 10 19% NA 36
Higgins et al. (2011) 2 52% 93% 12 23% 28 37
Holzgraefe et al. (2010) 1 92% 62% 16 8% NA NA
Noah et al. (2011) 4 NA 84% 9 29% NA NA
Patroniti et al. (2011) 2 47% 98% 10 32% 22 39
ECMO, extracorporeal membrane oxygenation; ICU, intensive care unit; NA, not available
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Outcomes were highly variable among the included
studies, with in-hospital or short-term mortality ranging
between 8% and 65%, mainly depending on patient base-
line features. Random-effect pooled estimates, albeit lim-
ited by underlying heterogeneity, suggested an overall
in-hospital mortality of 27.5% (95% confidence interval
18.4% to 36.7%; I2 = 64%), with a median intensive care
unit stay of 25 days, and an overall median total length
of stay of 37 days (Figure 2).
Exploratory meta-regression did not identify any sig-
nificant moderator of mortality (all P >0.05), but this
lack of statistical significance for established or likely
prognostic factors should be viewed in light of the lim-
ited statistical power of meta-regression, especially when
applied to a limited dataset. Finally, neither visual
inspection of funnel plots nor Peters test (P = 0.733)
suggested the presence of small study effects (Figure 3).
Discussion
This comprehensive systematic review, pooling data on
the outlook of ECMO in 266 patients with suspected or
confirmed H1N1 complicated with ARDS, have several
implications. First, ECMO appears feasible in young
patients with H1N1 or suspected H1N1 patients with
severe ALI. Accordingly, this treatment may represent a
promising alternative to standard protective ventilation.
Nonetheless, short-term survival can be further
improved, most likely by refinements in ancillary ther-
apy and means of mechanical ventilation.
The H1N1 influenza pandemic has generated a
plethora of research efforts, focusing on prevention,
diagnosis and treatment [19]. Indeed, such efforts have
been largely justified by the substantial risk of death
even in young and apparently healthy subjects develop-
ing fulminant ARDS [1,20]. Given these premises, the
application of current state-of-the-art ECMO technolo-
gies has been proposed as a promising means to reduce
the morbidity and mortality of ARDS, complicating sus-
pected or confirmed H1N1 influenza [2,21]. Despite the
availability of several recent studies focusing on the risk-
benefit balance of ECMO in this setting, the vast majority
of such publications are case reports or very small series.
Figure 1 Flow of information through the different phases of a systematic review.
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Even larger studies have usually a single center or single
country setting, and thus have limited external validity.
Given the superior statistical power and external valid-
ity of systematic reviews, our work provides important
insights on the clinical role of ECMO in the context of
H1N1 infection complicated by ALI. Indeed, ECMO
usage is feasible in this clinical setting, as testified by
the now large number of patients who have successfully
received this treatment, have been maintained on
ECMO for several days and have obtained a final satis-
factory clinical outcome. Thus, ECMO implementation
in this type of patients can be recommended in selected
centers provided training, logistics and resources are
adequate. Apparently, the positive results reported by
the included studies stemming from several interna-
tional tertiary care centers may be due to the short
Figure 2 Forest plot for the risk of mortality. CI, confidence interval; df, degrees of freedom; ECMO, extracorporeal membrane oxygenation;
SE, standard error.
Figure 3 Funnel plot for the risk of mortality (P = 0.733 at Peters test).
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period (median of two days) occurring between the start
of mechanical ventilation and the start of ECMO, the
elevated standards of the clinical centers that performed
ECMO, as suggested by the high referral rate, and the
young age of the treated patients (median 35 years).
However, further studies are required to confirm or dis-
prove the importance of these patient and procedural
factors to achieve favorable clinical results with ECMO
in ALI due to H1N1 infection. Notably, as many as 50%
of patients were transported under ECMO, a significant
undertaking which provides further evidence in support
of the safety of this modality of life support.
Quoting verbatim the Extracorporeal Life Support
Organization, the main indications for ECMO are acute
severe heart or lung failure with high mortality risk
despite optimal conventional therapy [22]. Thus, extra-
corporeal life support (ECLS) is considered when a 50%
mortality risk is predicted, whereas ECLS is patently
indicated in most circumstances at 80% mortality risk.
Severity of illness and mortality risk should be appraised
as precisely as possible using measurements for the
appropriate age group and organ failure. Most contrain-
dications are relative, balancing the risks of the proce-
dure (including the risk of using valuable resources
which could be employed for others) versus the potential
benefits. The relative contraindications are: 1) conditions
incompatible with normal life if the patient recovers; 2)
preexisting conditions which affect the quality of life
(central nervous system status, end stage malignancy, risk
of systemic bleeding with anticoagulation); 3) age and
size of the patient; and 4) futility: patients who are too
sick, have been on conventional therapy too long or have
a fatal diagnosis. The application of these guidelines in
the context of ARDS is jeopardized by the lack of clear
principles for selecting the venous-venous versus the
venous-arterial configuration [22].
Data in the literature are scarce, but a careful revision
of the patient population included in this systematic
review depicts a cohort of ARDS patients suffering from
severe circulatory failure and organ dysfunction or in
need of supramaximal inotropic support to maintain
hemodynamic stability. Accordingly, the care of these
patients still requires significant improvement. There are
also institutional issues that need to be addressed as the
treatment of these patients is variable in terms of alloca-
tion (general versus cardiothoracic intensive care units)
and specialists who are caring for them (intensive care
unit specialists versus cardiac surgeons). These differ-
ences necessarily bias the trends and attitudes in clinical
management.
We formally tried to explore the impact of veno-arterial
versus veno-venous ECMO by means of meta-regression,
given that the latter is usually associated with fewer
vascular complications, but may provide inadequate
hemodynamic support and less blood oxygenation in com-
parison to veno-arterial ECMO. On the other side, veno-
arterial ECMO is much more invasive in terms of vascular
access, risk of bleeding and may produce harlequin syn-
drome (that is, loco-regional and asymmetric discrepancies
in blood flow distribution appearing as differences in skin
color, sweating and temperature). However, we did not
find statistical evidence for a difference between these two
means to establish ECMO.
Despite the small number of patients, which has pre-
vented its inclusion in our meta-analysis, Roch and co-
workers reported a series of nine patients treated with
ECMO at a single institution for H1N1 ARDS. Among
them, six were treated with veno-venous and three with
veno-arterial ECMO. Baseline respiratory parameters were
not different between the two groups and both benefited
immediately from the extracorporeal support in terms of
gas exchange; whereas there was a striking difference
among survivors and non-survivors in terms of the hemo-
dynamic effects of ECMO: patients who died had no
improvement of circulatory function, as defined as
increased requirements or inability to wean from inotropic
agents or increased lactates [23].
The issue of cardiac failure in ARDS was also appraised
in detail by Brogan et al. in a retrospective revision of the
Extracorporeal Life Support Organization (ELSO) data-
base of adults treated for any respiratory failure [24].
They reported a steady increase in the utilization of the
veno-venous mode (from 44% in the period 1986 to 1991
to 72% in 2002 to 2006). However, more patients in the
most recent years required inotropic agents/vasopressors,
intra-aortic balloon pump (IABP) or had suffered preim-
plant cardiac arrest. Furthermore, Stöhr et al., in a series
of 30 patients, described a 40% need for primary veno-
arterial cannulation in patients suffering from ARDS and
an additional need for a change of configuration in 11
patients, mainly for insufficient oxygenation [25]. Inter-
estingly, the authors showed a configuration related mor-
tality: patients who received a veno-veno/arterial ECMO
displayed a decreased mortality when compared to
patients on veno-venous or veno-arterial mode (27% vs
63% vs 75%; P = 0.05).
The most recent case series included in this systema-
tic review is very promising [16]. The authors not only
confirmed the low mortality rate warranted by ECMO
but suggested, by a propensity score matching, that
referral and transfer to an ECMO center is associated
with 50% reduction in hospital mortality when com-
pared with matched non-ECMO-referred patients. Our
data, thus, confirm these and other authors’ results
showing the beneficial effects of ECMO for the treat-
ment of H1N1 ARDS.
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Limitations
This work has several limitations, including all those
typical of systematic reviews and meta-analyses. More-
over, pooling observational studies, this review cannot
overcome the limitations of primary studies, which were
of relatively high quality, but still none was based on
randomized allocation [26]. Indeed, only meta-analyses
of homogeneous randomized trials should be considered
the final scientific proof of the efficacy and safety of any
medical intervention. However, systematic reviews and
meta-analyses of non-randomized studies can be meaning-
ful and guide clinical research and practice, even if only by
emphasizing the limitations of the available clinical
evidence.
This meta-analysis is also not powerful enough to define
the exact role of different types of ECMO. Furthermore,
the exclusion of more than 70 reports because including
less than 10 cases clearly calls for more collaborative
research efforts. This type of collaboration is essential for
present and future clinical challenges resembling the
H1N1 pandemic. If only a fraction of these separate case
series were to be combined, we would have achieved
much greater statistical power and precision. In addition,
we did not formally appraise agreement between reviewers
before final consensus for study search, selection, abstrac-
tion or appraisal. Finally, no cases of H1N1 outbreaks have
been reported recently, and thus the main strength of the
present work is to prove that the experience with ECMO
for ALI due to H1N1 infection, given its favorable effects
on younger and previously healthier patients, may be help-
ful in the future in similar situations.
Conclusions
ECMO is feasible and effective in patients with ALI due to
H1N1 infection. Despite this, prolonged support (more
than one week) is required in most cases, and subjects
with severe comorbidities or multi-organ failure remain at
high risk of in-hospital death.
Key messages
• Eight case series with at least 10 patients each have
been published so far describing the use of ECMO
in patients with ALI due to H1N1 infection and
were summarized in this systematic review.
• The 266 ECMO patients were young (36 years old
on average), obese (39%), diabetic (11%) and asthmatic
or with chronic obstructive pulmonary disease (11%).
Notably, 20% of patients were females in the peri-
partum period.
• Patients received mechanical ventilation before
ECMO implementation for a median of two days,
were transferred to referral centers in 72% of cases and
mostly (94%) had a veno-venous ECMO implanted.
• ECMO was operated for a median of 10 days with
short-term mortality ranging between 8% and 65%
with a median intensive care unit stay of 25 days,
and an overall median total length of stay of 37 days.
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